Angelie Manaloto Santos
Nephrology · Las Vegas, NVNPI 1356838601
Payments from drug & device makers
Across 19 payments — averaging $37.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mozarc Medical US LLC$292
- Bayer$109
- Travere Therapeutics, Inc.$97
- Calliditas Therapeutics US Inc.$69
- Amgen$57
- Takeda Pharmaceuticals U.S.A., Inc.$24
- plus $63 from 3 others
What the payments were for
- Travel & lodging$395%
- Food & beverage$67195%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mozarc Medical US LLC | 3 | $292 |
| Bayer | 5 | $109 |
| Travere Therapeutics, Inc. | 3 | $97 |
| Calliditas Therapeutics US Inc. | 2 | $69 |
| Amgen | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Chameleon$186
How this compares
$710 in reported general payments places this provider in the 30th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lanthanum Carbonate | 12 | $6,830 |
| Sevelamer Carbonate | 14 | $711 |
| Nifedipine ErNifedipine | 21 | $609 |
| Calcitriol | 40 | $543 |
| Losartan Potassium | 27 | $295 |
| Lisinopril | 29 | $223 |
| Amlodipine Besylate | 11 | $133 |
| Furosemide | 14 | $108 |
| Carvedilol | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Las Vegas
- Mark VishnepolskyLas Vegas$11.3M
- Raj SinghLas Vegas$9.9M
- Samuel KantorLas Vegas$1M
- Jeffrey RyuLas Vegas$422K
- Lawrence LehrnerLas Vegas$239K
- Richard CottieroLas Vegas$220K
- Kamron SaleemLas Vegas$195K
- Mark AdaimyLas Vegas$142K
- Vincent YangLas Vegas$135K
- Prateek SangheraLas Vegas$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.